Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas.
anaplastic astrocytomas
apparent diffusion coefficient (ADC)
diffusion weighted imaging (DWI)
isocitrate dehydrogenase (IDH) mutation
overall survival
radiogenomics
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Apr 2020
23 Apr 2020
Historique:
received:
20
03
2020
revised:
16
04
2020
accepted:
21
04
2020
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
29
4
2020
Statut:
epublish
Résumé
The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) can noninvasively predict the most common IDH mutational status (R132H) in GIII-astrocytomas and the overall survival (OS). Hence, twenty-two patients (9-F, 13-M) with a histological diagnosis of GIII-astrocytoma and evaluation of IDH-mutation status (12-wild type, 10-mutant) were retrospectively evaluated. Imaging studies were reviewed for the morphological feature and mean ADC values (ADCm). Statistics included a Fisher's exact test, Student's
Identifiants
pubmed: 32340318
pii: diagnostics10040247
doi: 10.3390/diagnostics10040247
pmc: PMC7236014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neuroradiology. 2018 Jul;60(7):693-702
pubmed: 29777252
Int J Clin Oncol. 2020 Feb 4;:
pubmed: 32020379
Nat Rev Neurosci. 2003 Jun;4(6):469-80
pubmed: 12778119
Eur Radiol. 2019 Feb;29(2):745-758
pubmed: 30003316
Am J Pathol. 2009 Apr;174(4):1149-53
pubmed: 19246647
Eur J Radiol. 2010 Mar;73(3):532-7
pubmed: 19250783
Oncotarget. 2017 Jun 6;8(23):37884-37895
pubmed: 28039453
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
J Neurooncol. 2013 Apr;112(2):173-8
pubmed: 23358936
Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1904-9
pubmed: 25010621
Sci Rep. 2017 Mar 22;7:44792
pubmed: 28327577
Neuroradiology. 2016 Feb;58(2):121-32
pubmed: 26494463
AJNR Am J Neuroradiol. 2017 Jun;38(6):1138-1144
pubmed: 28450436
Acta Neuropathol. 2009 Oct;118(4):469-74
pubmed: 19554337
Insights Imaging. 2019 Dec 18;10(1):122
pubmed: 31853670
Acta Radiol. 2013 Mar 1;54(2):214-20
pubmed: 23138021
Oncol Lett. 2014 Jun;7(6):1895-1902
pubmed: 24932255
Ann Oncol. 2016 Apr;27(4):599-608
pubmed: 27005468
Sci Rep. 2015 Nov 05;5:16238
pubmed: 26538165
Acta Neuropathol. 2015 Jun;129(6):867-73
pubmed: 25962792
Magn Reson Imaging. 2018 Sep;51:158-162
pubmed: 29782920
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Brain Pathol. 2011 Jan;21(1):57-73
pubmed: 21129060
J Neurooncol. 2017 Dec;135(3):601-609
pubmed: 28871469
Medicine (Baltimore). 2020 Feb;99(8):e19254
pubmed: 32080132
Nat Genet. 2015 May;47(5):458-68
pubmed: 25848751
Br J Radiol. 2018 Jun;91(1086):20170696
pubmed: 29485906
Eur Radiol. 2020 Jun;30(6):3254-3265
pubmed: 32078014
J Clin Oncol. 2009 Sep 1;27(25):4150-4
pubmed: 19636000
J Neurooncol. 2005 May;72(3):273-80
pubmed: 15937653
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2015 Apr;129(4):585-96
pubmed: 25701198
Oncotarget. 2017 May 10;8(35):59492-59499
pubmed: 28938652
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Oncol. 2019 Feb;54(2):753-763
pubmed: 30483760
Sci Rep. 2020 Feb 28;10(1):3711
pubmed: 32111869